|Day Low/High||115.92 / 118.30|
|52 Wk Low/High||92.98 / 137.54|
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...
Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling...
Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.
Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.
Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.
The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.
Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.
Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.
Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including more than 150 oral presentations, evaluating Celgene investigational agents and investigational uses of marketed products will...
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4.
Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.
Cramer shares his views on why some still want to buy Bank of America. Wells Fargo, Celgene and Micron are among the stocks discussed.
Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.
It looks like CELG could retest the highs around $140.
Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American...
Doug Kass shares his thoughts on closed-end municipal bond funds.
Cramer shares his views on looking at oil now that the election is over. Starbucks, Kellogg and PepsiCo are among the stocks discussed.
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Cramer sees progress at Chipotle and takes a closer look at health care stocks.